Activist ATG Capital Sues Empery Digital Board for Entrenchment, Challenges Dilutive Offering and Poison Pill

summarizeSummary

Activist investor ATG Capital has filed a lawsuit against Empery Digital's board, alleging breaches of fiduciary duty and bylaws through entrenchment tactics, including a poison pill, dilutive stock issuance, and rejection of director nominations.

check_boxKey Events

• Lawsuit Filed Against Board

  ATG Capital, Empery Digital's largest disclosed shareholder (14.9% stake), has filed a Verified Complaint in the Delaware Court of Chancery against the company's entire board of directors.

• Allegations of Entrenchment Tactics

  The lawsuit accuses the board of a 'campaign of entrenchment' through multiple actions, including adopting a poison pill, accelerating share repurchases, and invalidly rejecting ATG's director nominations.

• Challenge to Dilutive Stock Issuance

  ATG specifically challenges the March 23, 2026, $25 million stock and warrant issuance to an undisclosed institutional investor, alleging it was a 'sweetheart deal' at an effective price of ~$2.50/share (vs. market price ~$4.50/share) designed to manipulate voting power.

• Seeking Injunctive Relief

  ATG is requesting the court to enjoin the board from enforcing the poison pill, using the accelerated share repurchase program, or relying on the contested stock issuance and rejection of nominations. It also seeks to sterilize the voting rights of shares from the March issuance.

auto_awesomeAnalysis

This filing reveals the full details of the lawsuit filed by activist investor ATG Capital against Empery Digital's entire board of directors. The complaint alleges severe breaches of fiduciary duty and company bylaws, accusing the board of a 'campaign of entrenchment' to thwart ATG's proxy contest. Key allegations include the adoption of a poison pill, accelerated share repurchases, a dilutive $25 million stock and warrant issuance to a 'friendly' institutional investor at a significant discount, and the invalid rejection of ATG's director nominations. This legal action escalates the ongoing battle for corporate control, creating significant uncertainty around the company's governance and the validity of recent capital raises. Investors should monitor the court's proceedings closely, as the outcome could fundamentally alter the company's leadership and strategic direction, especially given the company's recent 'going concern' warning and substantial losses.